Enlivex (ENLV) AI Stock Analysis

• Market Cap: $19.74M
• Dividend Yield: N/A
• Average Volume (3M): 195.99K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.32
• Revenue Growth: N/A
• EPS Growth: 32.42%
• Country: US
• Employees: 71
• Sector: Healthcare
• Sector Strength: 69
• Industry: Biotechnology
• EPS (TTM): -0.74
• Shares Outstanding: 21,989,536
• 10 Day Avg. Volume: 79,507
• 30 Day Avg. Volume: 195,988
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $7.00
• Price Target Upside: 677.78% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Enlivex's financial challenges, characterized by no revenue and ongoing cash burn, significantly impact its stock score. Technical indicators show neutral momentum, but the negative valuation metrics reflect ongoing financial difficulties. The absence of positive corporate events or earnings call data limits the potential for a higher score.

Positive Factors

Clinical Trials

The Danish Medicines Agency has authorized the initiation of the Phase 2 stage of the company’s multi-country Phase 1/2 trial in moderate and severe knee osteoarthritis (OA) patients.

Intellectual Property

Chinese patent claims allowed, covering Allocetra application in treatment of osteoarthritis, providing added intellectual property protection in China through at least 2040.

Safety Profile

The independent Data and Safety Monitoring Board (DSMB) has completed an interim data review at the conclusion of the Phase 1 safety run-in stage, confirming that the safety profile of Allocetra permits Enlivex to advance to the Phase 2 stage.

Negative Factors

Data Readouts Timeline

Enlivex may obtain top-line data readouts in two therapeutic areas (arthritic conditions and sepsis) across four trials by the end of 2025.

Enlivex Business Overview & Revenue Model

Company Description

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

How the Company Makes Money

Enlivex makes money primarily through the development and commercialization of its therapeutic candidates, particularly Allocetra. The company's revenue model is based on successful clinical trials leading to regulatory approvals, which would enable them to market and sell their therapies. Additionally, Enlivex may generate revenue through strategic partnerships, collaborations with pharmaceutical companies, and licensing agreements that provide upfront payments, milestone payments, and royalties on product sales. However, as a clinical-stage company, Enlivex is still in the process of establishing consistent revenue streams as it advances its therapies through clinical trials.

Enlivex Financial Statement Overview

Summary

Enlivex is facing challenges typical of early-stage biotechnology firms, with no revenue and ongoing losses. The firm needs to address its lack of revenue generation and improve cash flow management to ensure its financial viability. While the low debt offers some flexibility, the continuous cash burn and equity decline may limit future strategic options.

Income Statement

Enlivex has faced significant operational challenges with no reported revenue in recent periods, leading to negative gross and net margins. The consistent negative EBIT and EBITDA margins highlight ongoing profitability issues, with a lack of revenue growth exacerbating the financial strain.

Balance Sheet

The balance sheet reflects a relatively low debt-to-equity ratio, indicating limited leverage. However, the company's equity position has weakened over time as liabilities approach total assets, reducing the equity ratio. The declining stockholders' equity is a concern for financial stability.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, indicating operational inefficiencies and cash burn. Despite some cash inflows from financing activities, the company struggles to generate positive cash flow from operations, posing a risk to long-term sustainability.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	2.28M	0.00
	Gross Profit
-548.00K	-835.00K	-777.00K	-546.00K	1.99M	-297.00K
	EBIT
-16.15M	-29.39M	-25.80M	-19.29M	-9.79M	-8.62M
	EBITDA
-15.44M	-28.22M	-25.02M	-18.74M	-9.50M	-9.08M
	Net Income Common Stockholders
-18.93M	-29.07M	-42.41M	-9.65M	-13.86M	-10.15M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
5.55M	27.32M	48.12M	84.13M	35.71M	12.01M
	Total Assets
5.69M	36.83M	67.64M	95.15M	40.36M	17.56M
	Total Debt
0.00	1.03M	4.85M	617.00K	203.00K	123.00K
	Net Debt
-5.55M	219.00K	-42.98M	-10.59M	-5.47M	-3.83M
	Total Liabilities
131.00K	6.75M	10.80M	10.11M	4.87M	6.28M
	Stockholders Equity
5.55M	30.08M	56.84M	85.04M	35.49M	11.28M
Cash Flow		Free Cash Flow
-8.99M	-23.76M	-32.08M	-19.17M	-12.03M	-7.23M
	Operating Cash Flow
-13.95M	-23.52M	-23.95M	-17.54M	-11.01M	-7.04M
	Investing Cash Flow
9.80M	-25.97M	62.52M	-38.41M	-20.98M	-6.36M
	Financing Cash Flow
5.19M	360.00K	150.00K	60.98M	33.08M	8.31M

Enlivex Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENLV, the sentiment is Negative. The current price of 0.9 is below the 20-day moving average (MA) of 1.00, below the 50-day MA of 1.05, and below the 200-day MA of 1.24, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 38.70 is Neutral, neither overbought nor oversold. The STOCH value of 7.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENLV.

Enlivex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.35B	1.19	-46.26%	2.67%	19.24%	1.75%
ADAP	46 Neutral	$56.90M	―	-273.36%	―	194.23%	45.50%
CYCN	45 Neutral	$6.94M	―	-30.36%	―	―	86.52%
ALLO	41 Neutral	$315.03M	―	-55.13%	―	-86.25%	36.10%
ENLV	36 Underperform	$19.74M	―	-55.95%	―	―	32.42%
BLUE	36 Underperform	$50.42M	―	-295.35%	―	184.12%	31.92%
KPTI	36 Underperform	$36.10M	―	41.08%	―	-0.55%	49.85%